Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Association of polymorphisms of cytosine arabinoside-metabolizing enzyme gene with therapeutic efficacy for acute myeloid leukemia.

Xu PP, Chen BA, Feng JF, Cheng L, Xia GH, Li YF, Qian J, Ding JH, Lu ZH, Wang XM, Xu K, Schultz M.

Chin Med J (Engl). 2012 Jun;125(12):2137-43.

PMID:
22884143
2.

The associations of Janus kinase-2 (JAK2) A830G polymorphism and the treatment outcomes in patients with acute myeloid leukemia.

Zhong Y, Chen B, Feng J, Cheng L, Li Y, Qian J, Ding J, Gao F, Xia G, Chen N, Lu Z.

Leuk Lymphoma. 2010 Jun;51(6):1115-20. doi: 10.3109/10428191003774960.

PMID:
20536350
3.

Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.

Falk IJ, Fyrberg A, Paul E, Nahi H, Hermanson M, Rosenquist R, Höglund M, Palmqvist L, Stockelberg D, Wei Y, Gréen H, Lotfi K.

Am J Hematol. 2013 Dec;88(12):1001-6. doi: 10.1002/ajh.23549. Epub 2013 Sep 9.

4.

RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.

Abraham A, Varatharajan S, Karathedath S, Philip C, Lakshmi KM, Jayavelu AK, Mohanan E, Janet NB, Srivastava VM, Shaji RV, Zhang W, Abraham A, Viswabandya A, George B, Chandy M, Srivastava A, Mathews V, Balasubramanian P.

Pharmacogenomics. 2015 Jul;16(8):877-90. doi: 10.2217/pgs.15.44. Epub 2015 Jun 17.

5.

Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia.

Abraham A, Varatharajan S, Abbas S, Zhang W, Shaji RV, Ahmed R, Abraham A, George B, Srivastava A, Chandy M, Mathews V, Balasubramanian P.

Pharmacogenomics. 2012 Feb;13(3):269-82. doi: 10.2217/pgs.11.149.

PMID:
22304580
6.

SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival.

Mahlknecht U, Dransfeld CL, Bulut N, Kramer M, Thiede C, Ehninger G, Schaich M.

Leukemia. 2009 Oct;23(10):1929-32. doi: 10.1038/leu.2009.113. Epub 2009 May 21. No abstract available.

PMID:
19458626
8.

Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside.

Flasshove M, Strumberg D, Ayscue L, Mitchell BS, Tirier C, Heit W, Seeber S, Schütte J.

Leukemia. 1994 May;8(5):780-5.

PMID:
7514246
9.

[Single-nucleotide polymorphisms of the cytidine deaminase gene in childhood with acute leukemia and normal Chinese children].

Yue LJ, Chen XW, Li CR, Li CG, Shi HS, Zhang M.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2007 Dec;24(6):699-702. Chinese.

PMID:
18067088
10.

Combined interaction of multi-locus genetic polymorphisms in cytarabine arabinoside metabolic pathway on clinical outcomes in adult acute myeloid leukaemia (AML) patients.

Kim KI, Huh IS, Kim IW, Park T, Ahn KS, Yoon SS, Yoon JH, Oh JM.

Eur J Cancer. 2013 Jan;49(2):403-10. doi: 10.1016/j.ejca.2012.07.022. Epub 2012 Sep 7.

PMID:
22964418
11.

Polymorphisms in XPC provide prognostic information in acute myeloid leukemia.

Xu P, Chen B, Feng J, Cheng L, Xia G, Li Y, Qian J, Ding J, Lu Z.

Int J Hematol. 2012 Oct;96(4):450-60. doi: 10.1007/s12185-012-1145-3. Epub 2012 Sep 12.

PMID:
22968471
12.

Role of Genetic Polymorphisms of Deoxycytidine Kinase and Cytidine Deaminase to Predict Risk of Death in Children with Acute Myeloid Leukemia.

Medina-Sanson A, Ramírez-Pacheco A, Moreno-Guerrero SS, Dorantes-Acosta EM, Sánchez-Preza M, Reyes-López A.

Biomed Res Int. 2015;2015:309491. doi: 10.1155/2015/309491. Epub 2015 May 18.

13.

[Study on the relationship between human cytidine deaminase gene polymorphisms and Ara-C sensitivity].

Chen XW, Yue LJ, Li CR, Li CG, Shi HS, Zhang M.

Zhonghua Xue Ye Xue Za Zhi. 2008 Jul;29(7):459-63. Chinese.

PMID:
19035178
14.

Effect of genetic alterations of cytarabine- metabolizing enzymes in childhood acute lymphoblastic leukemia.

Banklau C, Jindadamrongwech S, Sawangpanich R, Apibal S, Hongeng S, Paisooksantivatana K, Pakakasama S.

Hematol Oncol Stem Cell Ther. 2010;3(3):103-8.

15.

Signal transducer and activator of transcription 3 (STAT3) gene polymorphisms are associated with treatment outcomes in acute myeloid leukemia.

Zhong Y, Feng J, Chen B, Cheng L, Li Y, Qian J, Ding J, Gao F, Xia G.

Int J Lab Hematol. 2012 Aug;34(4):383-9. doi: 10.1111/j.1751-553X.2012.01406.x. Epub 2012 Feb 29.

PMID:
22376160
16.

Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia.

Stam RW, den Boer ML, Meijerink JP, Ebus ME, Peters GJ, Noordhuis P, Janka-Schaub GE, Armstrong SA, Korsmeyer SJ, Pieters R.

Blood. 2003 Feb 15;101(4):1270-6. Epub 2002 Oct 24.

17.

Impact of single nucleotide polymorphisms of cytarabine metabolic genes on drug toxicity in childhood acute lymphoblastic leukemia.

Gabor KM, Schermann G, Lautner-Csorba O, Rarosi F, Erdelyi DJ, Endreffy E, Berek K, Bartyik K, Bereczki C, Szalai C, Semsei AF.

Pediatr Blood Cancer. 2015 Apr;62(4):622-8. doi: 10.1002/pbc.25379. Epub 2015 Jan 3.

PMID:
25557962
18.

Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.

Yamauchi T, Negoro E, Kishi S, Takagi K, Yoshida A, Urasaki Y, Iwasaki H, Ueda T.

Biochem Pharmacol. 2009 Jun 15;77(12):1780-6. doi: 10.1016/j.bcp.2009.03.011. Epub 2009 Mar 24.

PMID:
19428333
19.

Differential allelic expression in leukoblast from patients with acute myeloid leukemia suggests genetic regulation of CDA, DCK, NT5C2, NT5C3, and TP53.

Jordheim LP, Nguyen-Dumont T, Thomas X, Dumontet C, Tavtigian SV.

Drug Metab Dispos. 2008 Dec;36(12):2419-23. doi: 10.1124/dmd.108.023184. Epub 2008 Sep 5.

20.

The T_T genotype within the NME1 promoter single nucleotide polymorphism -835 C/T is associated with an increased risk of cytarabine induced neurotoxicity in patients with acute myeloid leukemia.

Braunagel D, Schaich M, Kramer M, Dransfeld CL, Ehninger G, Mahlknecht U.

Leuk Lymphoma. 2012 May;53(5):952-7. doi: 10.3109/10428194.2011.635862. Epub 2011 Dec 7.

PMID:
22035418

Supplemental Content

Support Center